Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CP-675,206 in patients with hepatocellular carcinoma and hepatitis C virus infection
2008-001177-15Phase 2Completed
- Sponsor
- Cima Universidad de Navarra
- Start
- Jun 2008
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in hepatocellular carcinoma (HCC), sponsored by Cima Universidad de Navarra. Primary endpoint: Objective tumor response. Started Jun 2008; status: completed.
02
Drugs
tremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-001177-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001177-15.